A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Sponsored by Amgen
About this study
The primary objectives are to compare progression-free survival (PFS) and overall survival (OS) in participants who receive sotorasib with platinum doublet chemotherapy versus participants who receive pembrolizumab with platinum doublet chemotherapy.
Where this study is enrolling (2)
- Call 877-632-6789
University of Texas MD Anderson Cancer Center
Houston, Texas
This research site can be reached directly by phone. Call to ask about this study.
Create a free account to get updates on similar Clinical Trials for your conditions.
- Call 855-827-9525
Oncology Consultants PA
Houston, Texas
This research site can be reached directly by phone. Call to ask about this study.
Create a free account to get updates on similar Clinical Trials for your conditions.
Who can participate
Inclusion criteria
- ✓Histologically or cytologically confirmed diagnosis of nonsquamous stage IV or advanced Stage IIIB or IIIC NSCLC with KRAS p. G12C mutation and negative for PD-L1 expression by central testing or local laboratory testing confirmed through central testing
- ✓No history of systemic anticancer therapy in metastatic/non-curable settings
- ✓Eastern Cooperative Oncology Group (ECOG) ≤ 1
Exclusion criteria
- ✕Mixed histology NSCLC with either small-cell or large-cell neuroendocrine cell component or predominant squamous cell histology
- ✕Participants with tumors known to harbor molecular alterations for which targeted therapy is locally approved as a front-line therapy
- ✕Symptomatic (treated or untreated) brain metastases
- ✕Gastrointestinal (GI) tract disease causing the inability to take oral medication
- ✕Myocardial infarction within 6 months of randomization, unstable arrhythmias, or unstable angina
- ✕Prior therapy with a KRAS G12C inhibitor
Only the research team can confirm whether you qualify. The intake questionnaire is the best way to find out.
Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.
Trial data sourced from ClinicalTrials.gov.